Tag Archives: MARA

4 Crypto Stocks to Buy as Bitcoin Adoption Increases

The total number of cryptocurrency users globally were 106 million as of January 2021. The surge in number of global users has been unprecedented in the last few months. Thus, this rise has cause a number of crypto stocks to be a hot commodities for investors.

In June 2021, the crypto users globally more than doubled to 221 million. Clearly, adoption of Bitcoin (CCC:BTC-USD) has been growing at a stellar pace with big participation coming from institutional investors.

From a price action perspective, the worst seems to be over for Bitcoin. The cryptocurrency has been trading higher with rising adoption being one factor. Furthermore, Tesla (NASDAQ:TSLA) is likely to start accepting Bitcoin again as a payment method. With real interest rates remaining negative in most parts of the world, Bitcoin is likely to witness sustained fund inflow.

One way for exposure to the world of cryptocurrencies is through crypto stocks. There are listed companies involved in the mining of Bitcoin and Ethereum (CCC:ETH-USD). Additionally, decentralized finance promises to be big in the coming years. Crypto companies are likely to diversify beyond just mining.

Therefore, with growth at an inflection point, it’s a good idea to have some crypto stocks in your portfolio. Thus, let’s talk about four crypto stocks that look interesting from a medium to long-term investment perspective.

Marathon Digital (NASDAQ:MARA) Riot Blockchain (NASDAQ:RIOT) Coinbase (NASDAQ:COIN) Robinhood (NASDAQ:HOOD)

Now, let’s dive in and take a closer look at each one.

Crypto Stocks to Buy: Marathon Digital (MARA)
Image of cryptocurrency tokens in a wallet.Image of cryptocurrency tokens in a wallet.

Source: stockphoto-graf / Shutterstock.com

MARA stock has surged by 194% in 2021, and looks good for further upside. The Bitcoin mining company is positioned for strong revenue growth in the next few years as it aggressively acquires miners.

Recently, the company reported second-quarter results for 2021 and revenue surged by 10,147% year-over-year (YOY) to $29.3 million. For the quarter, the company mined a total of 654 Bitcoins with 19,395 miners deployed.

The key point to note is that Marathon expects to increase the number of miners to 103,120 by Q1 2022. This would represent 6.4% of the global Bitcoin hash rate. Therefore, as the number of miners increase, the company is positioned for sustained growth.

Once all miners are deployed, the company expects to deliver revenue of $94.4 million per month at $55,000 Bitcoin. This would imply an annualized revenue in excess of $1 billion.

It’s also worth noting that as of Q2 2021, the company reported cash and equivalents of $170.6 million. Furthermore, the value of cash and Bitcoin holdings was $366.5 million. This gives the company ample financial headroom to pursue growth even beyond the current expansion plan.

Overall, MARA stock is among the one of the most attractive crypto stocks — and fresh exposure can be considered at current levels.

Riot Blockchain (RIOT)
An image of a hand holding a cell phone with several visualizations of digital building blocks floating above it. representing sto platformsAn image of a hand holding a cell phone with several visualizations of digital building blocks floating above it. representing sto platforms

Source: Marko Aliaksandr/ShutterStock.com

After a massive rally in the last 12 months, RIOT stock has seen some consolidation as of late. A renewed rally seems likely with the company having ambitious growth plans.

Currently, Riot Blockchain has a total hash rate capacity of 1.6 EH/s. The company plans to ramp-up capacity of 7.7 EH/s by Q4 2022.

It’s worth noting that for Q1 2022, the company mined 5.46 Bitcoin in a daily basis. Given the expansion plans, the company is well positioned to mine 20 to 25 Bitcoins on a daily basis. This would imply a five-fold revenue growth in the next 12-18 months.

For Q1 2021, Riot reported revenue of $23.2 million. For the same period, the company’s adjusted EBITDA was $10.3 million. This implies an EBITDA margin of 44%. With the coming expansion, the company is positioned for healthy EBITDA and cash flows.

Riot also reported cash and Bitcoin value of $275.6 million as of Q1 2022. Additionally, the company had zero debt. Therefore, there is ample financial flexibility to fund the growth plan.

I would not be surprised if Riot pursues acquisition drive growth once the current expansion plan is completed. Therefore, RIOT stock is among the quality crypto stocks to consider for the medium to long-term.

Crypto Stocks to Buy: Coinbase (COIN)
The Coinbase (COIN) logo on a smartphone screen with a BTC token.The Coinbase (COIN) logo on a smartphone screen with a BTC token.

Source: Primakov / Shutterstock.com

After a stellar listing and highs of $429, COIN stock has been in a correction and consolidation mode. At a forward price-earnings (P/E) ratio of 21.98, the stock looks attractive. A break-out on the upside seems imminent with rising adoption of cryptocurrencies

Talking about the rising adoption, global crypto users had surged past 100 million earlier this year. Within four months, the number of crypto users doubled to 221 million. Clearly, this is a big positive for Coinbase.

Specific to Coinbase, the retail trading volume on the platform was $11 billion in Q2 2020 and it surged to $145 billion in Q2 2021. For the same period, the institutional trading volume increased from $17 billion to $317 billion. Therefore, there has been wide adoption among institutional investors.

Another important point from the financial perspective is the company’s reported EBITDA of $1.2 billion for Q2 2021. This would imply an annualized EBITDA of $4.8 billion.

The company also reported operating cash flow of $2.2 billion (excluding custodial funds due to customers) for the first half of 2021. Therefore, Coinbase seems positioned to generate robust free cash flows in the coming years.

It seems like a good opportunity to accumulate COIN stock at current levels. The company’s asset-light business is likely to be a cash flow machine as crypto users continue to increase at a healthy pace.

Robinhood (HOOD)
Robinhood stocks: app logo seen on smartphone on US dollar banknotesRobinhood stocks: app logo seen on smartphone on US dollar banknotes

Source: mundissima / Shutterstock.com

HOOD stock has witnessed significant volatility after the initial public offering (IPO). However, the stock looks good for the long-term with the company on a high-growth trajectory.

Currently, Robinhood offers trading and investment options for stocks, funds, gold and cryptocurrencies. Therefore, the offering is more diversified.

On the flip-side, the company’s presence in just in the United States. However, it seems very likely that Robinhood will pursue expansion in international markets in the coming years.

According to the company’s prospectus, Robinhood had 17.7 million monthly active customers with $81 billion in assets under custody. It’s also worth noting that the company’s average revenue per user (ARPU) was $37 in 2017. However, for 2020, the ARPU has increased to $108.9. Sustained growth in ARPU points to healthy EBITDA margin and cash flows in the coming years.

In terms of top-line growth, Robinhood reported revenue of $959 million for 2020. YOY, revenue was higher by 245%. Clearly, the company is on a robust growth trajectory. This makes HOOD stock attractive.

Specific to cryptocurrencies, Robinhood reported assets under custody (AUC) of $481 million as of March 2020. The total crypto assets under custody increased to $11.6 billion as of March 2021. The growth has been stellar and considering the rate of cryptocurrency adoption, AUC will continue to witness strong growth.

On the date of publication, Faisal Humayun did not have (either directly or indirectly) any positions in any of the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Faisal Humayun is a senior research analyst with 12 years of industry experience in the field of credit research, equity research and financial modeling. Faisal has authored over 1,500 stock specific articles with focus on the technology, energy and commodities sector.

30 Stocks Moving In Friday's Mid-Day Session

ShiftPixy Inc (NASDAQ: PIXY) shares climbed 97 percent to $4.27 following Q4 earnings report. ShiftPixy reported sales of $20.244 million in the fourth quarter, up from $8.46 million year-over-year. The company sees first quarter gross billings of $40 million.
Longfin Corp (NASDAQ: LFIN) shares climbed 56.8 percent to $8.45 after the company announced agreement to acquire Ziddu.com.
Diana Containerships Inc (NASDAQ: DCIX) shares rose 22.59 percent to $5.97 after falling 7.06 percent on Thursday.
Riot Blockchain, Inc. (NASDAQ: RIOT) shares climbed 14.51 percent to $28.605 after gaining 8.47 percent on Thursday.
Wins Finance Holdings Inc (NASDAQ: WINS) shares gained 14.2 percent to $136.00.
Educational Development Corporation (NASDAQ: EDUC) shares rose 13.1 percent to $16.00 after the company reported Q3 and year-to-date revenue.
Crocs, Inc. (NASDAQ: CROX) climbed 12.4 percent to $12.30. Stifel Nicolaus upgraded Crocs from Hold to Buy.
TiGenix NV (NASDAQ: TIG) gained 12.4 percent to $24.36. Takeda and TiGenix disclosed that Cx601 has received a positive CHMP opinion for treatment of complex perianal fistulas in Crohn's disease. Mesoblast has granted Tigenix exclusive global patent license to use adipose-derived mesenchymal stem cells in local treatment of fistulae.
Marathon Patent Group Inc (NASDAQ: MARA) jumped 10.8 percent to $6.0206 after falling 4.57 percent on Thursday.
Professional Diversity Network Inc (NASDAQ: IPDN) shares rose 10 percent to $4.10.
Under Armour Inc (NYSE: UAA) shares jumped 9 percent to $15.06. Stifel Nicolaus upgraded Under Armour from Hold to Buy.
FormFactor, Inc. (NASDAQ: FORM) shares gained 8.8 percent to $16.21.
DDR Corp (NYSE: DDR) climbed 8.8 percent to $8.66 after announcing the the creation of a retail value trust, which will be spun off with approximately $3 billion of Gross Book Value of assets and business. The company will complete the portfolio transformation while maintaining scale and balance sheet strength and that the strategy will realize private market asset values.
Galapagos NV (ADR) (NASDAQ: GLPG) shares gained 7.4 percent to $90.71 after the company reported that it has exercised co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries.
Hess Corp. (NYSE: HES) climbed 4.7 percent to $44.42 after a WSJ report says that activist investor Elliott seeks to replace John Hess as CEO or get him to consider a sale. The activist investor also seeks a dividend cut and more buybacks.
U.S. Global Investors, Inc. (NASDAQ: GROW) gained 4.6 percent to $5.915 after climbing 7.82 percent on Thursday.
RumbleON Inc (NASDAQ: RMBL) shares gained 3.1 percent to $5.4594 after announcing a strategic partnership with Sonic Automotive Inc (NYSE: SAH).

Losers
TrovaGene Inc (NASDAQ: TROV) shares dipped 43.1 percent to $0.2449. Trovagene priced its 15 million share common stock offering at $0.30 per share.
One Horizon Group Inc (NASDAQ: OHGI) shares dipped 21.1 percent to $2.4299 after surging 185.16 percent on Thursday.
Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares dropped 15.6 percent to $0.53 after the company agreed to be acquired by Genoptix for $10 million.
Verastem Inc (NASDAQ: VSTM) shares declined 12.1 percent to $3.21 after announcing public offering of common stock.
Frontier Communications Corp (NASDAQ: FTR) dropped 10 percent to $8.6401. Barclays initiated coverage on Frontier Communications with an Underweight rating and a $7.00 price target.
Fitbit Inc (NYSE: FIT) shares dropped 7.7 percent to $6.2950. Stifel Nicolaus downgraded Fitbit from Hold to Sell.
CSX Corporation (NYSE: CSX) dipped 7.7 percent to $52.88 following announcement that the CEO Hunter Harrison had taken medical leave.
Oracle Corporation (NYSE: ORCL) shares declined 5.6 percent to $47.37. Oracle posted upbeat earnings for its second quarter, but revenue from its cloud-based business missed analysts' estimates.
SG Blocks Inc (NASDAQ: SGBX) shares slipped 5.5 percent to $5.20.
Global Blood Therapeutics Inc (NASDAQ: GBT) fell 5.3 percent to $37.30. Global Blood Therapeutics reported a $100 million common stock offering.
bebe stores, inc. (NASDAQ: BEBE) shares fell 5.1 percent to $4.10.
Yield10 Bioscience Inc (NASDAQ: YTEN) shares dropped 5 percent to $3.45 after dropping 17.153 percent on Thursday.
The Chefs' Warehouse, Inc. (NASDAQ: CHEF) slipped 2.7 percent to $19.50 after the company reported commencement of public offering of common stock.

30 Stocks Moving In Friday's Mid-Day Session

ShiftPixy Inc (NASDAQ: PIXY) shares climbed 97 percent to $4.27 following Q4 earnings report. ShiftPixy reported sales of $20.244 million in the fourth quarter, up from $8.46 million year-over-year. The company sees first quarter gross billings of $40 million.
Longfin Corp (NASDAQ: LFIN) shares climbed 56.8 percent to $8.45 after the company announced agreement to acquire Ziddu.com.
Diana Containerships Inc (NASDAQ: DCIX) shares rose 22.59 percent to $5.97 after falling 7.06 percent on Thursday.
Riot Blockchain, Inc. (NASDAQ: RIOT) shares climbed 14.51 percent to $28.605 after gaining 8.47 percent on Thursday.
Wins Finance Holdings Inc (NASDAQ: WINS) shares gained 14.2 percent to $136.00.
Educational Development Corporation (NASDAQ: EDUC) shares rose 13.1 percent to $16.00 after the company reported Q3 and year-to-date revenue.
Crocs, Inc. (NASDAQ: CROX) climbed 12.4 percent to $12.30. Stifel Nicolaus upgraded Crocs from Hold to Buy.
TiGenix NV (NASDAQ: TIG) gained 12.4 percent to $24.36. Takeda and TiGenix disclosed that Cx601 has received a positive CHMP opinion for treatment of complex perianal fistulas in Crohn's disease. Mesoblast has granted Tigenix exclusive global patent license to use adipose-derived mesenchymal stem cells in local treatment of fistulae.
Marathon Patent Group Inc (NASDAQ: MARA) jumped 10.8 percent to $6.0206 after falling 4.57 percent on Thursday.
Professional Diversity Network Inc (NASDAQ: IPDN) shares rose 10 percent to $4.10.
Under Armour Inc (NYSE: UAA) shares jumped 9 percent to $15.06. Stifel Nicolaus upgraded Under Armour from Hold to Buy.
FormFactor, Inc. (NASDAQ: FORM) shares gained 8.8 percent to $16.21.
DDR Corp (NYSE: DDR) climbed 8.8 percent to $8.66 after announcing the the creation of a retail value trust, which will be spun off with approximately $3 billion of Gross Book Value of assets and business. The company will complete the portfolio transformation while maintaining scale and balance sheet strength and that the strategy will realize private market asset values.
Galapagos NV (ADR) (NASDAQ: GLPG) shares gained 7.4 percent to $90.71 after the company reported that it has exercised co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries.
Hess Corp. (NYSE: HES) climbed 4.7 percent to $44.42 after a WSJ report says that activist investor Elliott seeks to replace John Hess as CEO or get him to consider a sale. The activist investor also seeks a dividend cut and more buybacks.
U.S. Global Investors, Inc. (NASDAQ: GROW) gained 4.6 percent to $5.915 after climbing 7.82 percent on Thursday.
RumbleON Inc (NASDAQ: RMBL) shares gained 3.1 percent to $5.4594 after announcing a strategic partnership with Sonic Automotive Inc (NYSE: SAH).

Losers
TrovaGene Inc (NASDAQ: TROV) shares dipped 43.1 percent to $0.2449. Trovagene priced its 15 million share common stock offering at $0.30 per share.
One Horizon Group Inc (NASDAQ: OHGI) shares dipped 21.1 percent to $2.4299 after surging 185.16 percent on Thursday.
Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares dropped 15.6 percent to $0.53 after the company agreed to be acquired by Genoptix for $10 million.
Verastem Inc (NASDAQ: VSTM) shares declined 12.1 percent to $3.21 after announcing public offering of common stock.
Frontier Communications Corp (NASDAQ: FTR) dropped 10 percent to $8.6401. Barclays initiated coverage on Frontier Communications with an Underweight rating and a $7.00 price target.
Fitbit Inc (NYSE: FIT) shares dropped 7.7 percent to $6.2950. Stifel Nicolaus downgraded Fitbit from Hold to Sell.
CSX Corporation (NYSE: CSX) dipped 7.7 percent to $52.88 following announcement that the CEO Hunter Harrison had taken medical leave.
Oracle Corporation (NYSE: ORCL) shares declined 5.6 percent to $47.37. Oracle posted upbeat earnings for its second quarter, but revenue from its cloud-based business missed analysts' estimates.
SG Blocks Inc (NASDAQ: SGBX) shares slipped 5.5 percent to $5.20.
Global Blood Therapeutics Inc (NASDAQ: GBT) fell 5.3 percent to $37.30. Global Blood Therapeutics reported a $100 million common stock offering.
bebe stores, inc. (NASDAQ: BEBE) shares fell 5.1 percent to $4.10.
Yield10 Bioscience Inc (NASDAQ: YTEN) shares dropped 5 percent to $3.45 after dropping 17.153 percent on Thursday.
The Chefs' Warehouse, Inc. (NASDAQ: CHEF) slipped 2.7 percent to $19.50 after the company reported commencement of public offering of common stock.

5 Top Biotech Penny Stocks to Buy with Huge Catalysts in January 2018

Few investments have the profit potential of penny stocks, which are stocks that trade under $5 per share.

Just take a look at Marathon Patent Group Inc. (Nasdaq: MARA), which climbed an astounding 341% during the four trading days of Thanksgiving week.

Biotech penny stocks are especially attractive since successful clinical trial results for their drugs can often send their share prices soaring 300%-plus.

That’s why today we’re giving you five of the top biotech penny stocks to buy that are all reporting clinical trial results in January 2018.

If a stock’s clinical trial results are positive, then the stock can soar. For example, the first stock on this list shot up 213% in July after the U.S. Food and Drug Administration (FDA) accepted the resubmission of its New Drug Application (NDA) for one of its drugs.

Receiving FDA approval for an NDA is typically the last major benchmark a drug must pass before it can be launched.

While these stocks have huge profit potentials, you must keep in mind that penny stocks are very speculative investments. They often see big pullbacks after making large gains.

That’s why Money Morning recommends that no more than 2% of your stock portfolio consist of such risky investments.

But if you’re willing to take the risk, some of these stocks could bring you profits of over 300% next year.

FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Now get comfy and grab your calendar, because here’s the first biotech penny stock on our list today…

Biotech Penny Stocks to Buy for January, No. 5: Aeterna Zentaris Inc.

Currently trading at $2 per share, Aeterna Zentaris (Nasdaq: AEZS) makes the drug Macrilen as a potential treatment for growth hormone deficiency in adults.

On July 18, the company announced the FDA accepted its NDA for Macrilen for review. This news sent AEZS shares up from $1.02 to $3.20 in just three trading days, for a gain of 213%.

top biotech penny stocks to buymoneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine-75×113.png 75w, moneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine.png 300w” sizes=”(max-width: 200px) 100vw, 200px” title=”top biotech penny stocks to buy” />

Still, before Aeterna can launch the drug Macrilen, its resubmitted NDA must be approved by the FDA. The FDA will announce if it approves Aeterna’s resubmitted NDA on Dec. 30.

Company officials are confident the company will be able to launch Macrilen sometime in the first quarter of 2018.

Keep an eye on AEZS shares leading up to the Dec. 30 announcement, and buy only if you believe the FDA will approve the NDA.

Up next is a stock with a drug that has three chances to pass phase 3 clinical trials…

Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc.

Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.

Unlike other biotech penny stocks, shares of AXSM aren’t “all in” on just one drug’s results.

Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.

Specifically, we’re going to focus on Axsome’s AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.

VideoMeet the Trading Expert Who Could Help Make You a Millionaire

If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.

The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it’s likely that AXS-02’s results will come out first.

The next company we’ll show you is the cheapest on this list…

Biotech Penny Stocks to Buy for January, No. 3: BioLine Rx Ltd.

Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

BioLine has partnerships with major pharmaceutical companies that help bring some of these drugs to launch once they gain some initial success in clinical trials. These partners include Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK).

Like Axsome Therapeutics, BioLine is less risky than other biotech penny stocks that only have a single drug in development or single partner. But BioLine’s risk profile is even more diverse, with eight drugs in development and multiple major partnerships to help support it.

The company’s leading drug BL-8040 is being tested in three different phase 2 clinical trials in 2018. The first trial is for the drug’s treatment of pancreatic cancer. Partial data of the trial will be presented between Jan. 18 and 20 at the ASCO 2018 Gastrointestinal Cancers Symposium.

Next up is a company which makes a drug that could provide millions of Americans with the relief they so deserve…

Join the conversation. Click here to jump to comments…

Come Talk About Bitcoin Next Week With Our All-Star Panel

Come Talk About Bitcoin Next Week With Our All-Star Panel

After striking new all-time highs in a matter of days, bitcoin trades three times higher than it did a month ago.

Bulls expect it to break $20,000 imminently, but the cryptocurrency’s fate is far from certain. Skeptics maintain the bitcoin bubble will burst amid the recent launch of futures, while agnostics confess enduring confusion.

To help make sense of the complicated trend, Benzinga will bring together some of the Street’s vying voices next week during the PreMarket Prep Bitcoin Special on Dec. 19.

What Can I Learn?

Co-hosts Joel Elconin and Dennis Dick will moderate an expert panel discussing the basics and complexities of cryptocurrency, including its potential to become a new asset class, the threat of a bubble, evaluation of fair price, the mechanics of mining, the effects of futures trading and the prospects of government regulation.

They will also weigh exposure opportunities in peripheral stocks and ETFs, including Riot Blockchain Inc (NASDAQ: RIOT), Social Reality Inc (NASDAQ: SRAX), Marathon Patent Group Inc (NASDAQ: MARA), Digital Power Corporation (NYSE: DPW) and Xunlei Ltd (NASDAQ: XNET).

Who Are The Guests?

The panel will feature experts with opposing perspectives on cryptocurrency:

Jeff Goldman, a long-time bitcoin trader and author of “Failed Traders: The 20 Common Mistakes Committed By Over 1,000 Losing Traders;”
Joe Saluzzi, bitcoin critic and partner and co-founder of Themis Trading;
Michael Graub, bitcoin trader through a private family office.
Peter Schiff, CEO and Chief Global Strategist at Euro Pacific Capital
Michael Sonnenshein, Investments Director at Grayscale, sponsor of the Bitcoin Investment Trust (OTC: GBTC)
Where and When?

The free webinar will run Tuesday, Dec. 19, from 8 a.m. to 9:30 a.m. EST. Register for the webinar here!